Bimiralisib is under clinical development by Torqur and currently in Phase II for Actinic (Solar) Keratosis. According to GlobalData, Phase II drugs for Actinic (Solar) Keratosis have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bimiralisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bimiralisib overview

Bimiralisib (PQR-309) is under development for the treatment of cutaneous T cell lymphoma and actinic keratosis. The therapeutic candidate is administered through oral and topical route as gel. PQR-309 targets all isoforms of PI3K and mTOR. It is developed using high-throughput and low-throughput-high-output discovery and validation platforms.

The drug candidate was also under development for the treatment of metastatic HER2 negative and triple-negative breast cancer, solid tumors, diffuse large B-cell lymphoma, relapsed/refractory chronic lymphoid leukemia and primary CNS lymphoma, inflammation, plaque psoriasis, glioblastoma multiforme, recurrent head and neck squamous cell carcinoma, eye, central nervous system disorders.

Torqur overview

Torqur, (Torqur), a subsidiary of Swiss Rockets, develops novel anticancer therapeutics targeting the metabolic PI3K/mTOR intracellular signalling pathway. Torqur is headquartered in Basel, Switzerland.

For a complete picture of Bimiralisib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.